NCT00782106CompletedPhase 1
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Baxalta now part of Shire3 sites in 1 country11 target enrollmentStarted: December 4, 2006Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 11
- Locations
- 3
- Primary Endpoint
- Ability to administer, after priming with recombinant human hyaluronidase, at least one half of a 4-week dose (minimum of 200 mg/kg) of IgG in a single infusion site, via the subcutaneous route, with no more than mild local adverse drug reactions.
Study Overview
Brief Summary
The purpose of the study is to determine the feasibility of infusing a full 4-week dose of Immune Globulin Intravenous (Human), 10% in a single subcutaneous site and the amount of recombinant human hyaluronidase needed to infuse that dose with no more than mild local adverse drug reactions.
Study Design
- Study Type
- Interventional
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 16 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Written informed consent from either the subject or the subject's legally acceptable representative
- •Diagnosis of a PID disorder as defined by World Health Organization criteria1 for which the subject had been receiving a regimen of weekly or biweekly (every-other-week) subcutaneous IgG infusions or IGIV infusions every 21 to 28 days over a period of at least 8 weeks pre-study at an equivalent of a 4-week dose of 300 to 800 mg/kg bodyweight
- •Adults/adolescents aged 16 years and older)
- •For female subjects of child-bearing age: negative urine pregnancy test result at study entry and agreement to employ adequate birth control measures for the duration of the study
Exclusion Criteria
- •Subjects positive at enrollment for one or more of the following: HBsAg, PCR for HCV, PCR for HIV Type 1
- •Subjects with levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal for the testing laboratory
- •Subjects with neutropenia (defined as an absolute neutrophil count [ANC] <= 500/mm3).
- •Subjects with serum creatinine levels greater than 1.5 times the upper limit of normal for age and gender
- •Subjects with current history of malignancy
- •Subjects with a history of thrombotic episodes (deep vein thrombosis, myocardial infarction, cerebrovascular accident)
- •Subjects with abnormal protein loss (protein losing enteropathy, nephritic syndrome, severe lung disease)
- •Subjects with anemia that in the opinion of the investigator precluded phlebotomy for laboratory studies
- •Subjects who had been exposed to any blood or blood product other than an intravenous immunoglobulin (IGIV), SC immunoglobulin (SCIG), immune serum globulin (ISG) preparations, or albumin within the 6 months prior to study entry.
- •Subjects with an ongoing history of hypersensitivity or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IGIV, SCIG and/or ISG infusions
- •Subjects with IgA deficiency and known anti IgA antibodies
- •Subjects who had received antibiotic therapy for the treatment of infection within 7 days prior to enrollment
- •Subjects who had participated in another clinical study involving an investigational product or device within 28 days prior to study entry
- •Subjects with inability or unwillingness to meet all the requirements of this study
- •If female, pregnancy or lactation at time of study entry
Arms & Interventions
1
Experimental
Tolerability of subcutaneous infusions
Intervention: Recombinant human hyaluronidase + immune globulin intravenous (Biological)
2
Experimental
Tolerability of subcutaneous infusions and pharmacokinetics
Intervention: Recombinant human hyaluronidase + immune globulin intravenous (Biological)
Outcomes
Primary Outcomes
Ability to administer, after priming with recombinant human hyaluronidase, at least one half of a 4-week dose (minimum of 200 mg/kg) of IgG in a single infusion site, via the subcutaneous route, with no more than mild local adverse drug reactions.
Time Frame: 72 hours
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (3)
Loading locations...
Similar Trials
Completed
Phase 2
ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell LungNCT00071188Genzyme, a Sanofi Company
Completed
Phase 1
A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older AdultsInfluenza, HumanNCT05823974GlaxoSmithKline1,275
Completed
Phase 1
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT06532032Janssen Research & Development, LLC12
Active, not recruiting
Phase 1
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT05908734Janssen Research & Development, LLC71
Completed
Phase 1
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular CarcinomaCarcinoma, HepatocellularNCT02421185Janssen Research & Development, LLC53